Progenics Corporation

The Jackson Laboratory

Jackson Lab.

Norman Applezweig

Douglas L Coleman

H Leon Bradlow

Edward H Leiter

Methods and compositions are disclosed for inducing an incresed blood level of alpha-etiocholanolone in the body of a mammal in need of such treatments comprising administering to said mammal an amount of etiocholanedione effective to induce said increased blood level.

Increasing the bioavailability of alpha-etiocholanolone

Obesity and diabetes obesity syndromes are treated with 5.beta.-sapogenin or .DELTA..sup.5 sapogenin.

Treatment of obesity and diabetes using sapogenins

Obesity, diabetes obesity syndromes and associated hypercorticoidism are treated with .alpha. and/or .beta.-etiocholanolone.

Treatment of obesity, diabetes and other symptoms of hypercorticoidism

Diabetes is treated by orally administering a dehydroepiandrosterone (DHEA) compound selected from the group consisting of DHEA, DHEA sulfate and soluble DHEA compounds. The DHEA compound is preferably administered in finely dispersed form, powdered or solution, mixed with the food diet of the diabetic in a dosage range of up to 0.4% by weight of the food diet. The pharmacological activity and utility of DHEA as a potent anti-diabetic agent and anti-hyperglycemic agent over a variable range of genetic background is documented.

Method for treating diabetes using DHEA compounds

Diabetes obesity syndromes and associated hypercorticoidism are treated with a synergistic combination of .alpha.- and/or .beta.-etiocholanolone and an estrogen.

Growing community of inventors

New York, NY, United States of America

Norman Applezweig